Evidence map›Paper›PMID 33318007›Full record

Observational studyAntimicrobial agents and chemotherapy2021

Claire L Keating, Jonathan B Zuckerman, Pradeep K Singh, Matthew McKevitt, Oksana Gurtovaya, Mark Bresnik, Bruce C Marshall, Lisa Saiman

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Antibiotics (Basel, Switzerland) · 2021
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Claire L KeatingDivision of Pulmonary, Allergy and Critical Care, Columbia University Irving Medical Center, New York, New York, USA ck2132@cumc.columbia.edu.
Jonathan B ZuckermanDivision of Pulmonary and Critical Care, Maine Medical Center, Portland, Maine, USA.
Pradeep K SinghDepartment of Microbiology and Medicine, University of Washington, Seattle, Washington, USA.
Matthew McKevittGilead Sciences, Inc., Seattle, Washington, USA.
Oksana GurtovayaGilead Sciences, Inc., Foster City, California, USA.
Mark BresnikGilead Sciences, Inc., Foster City, California, USA.
Bruce C MarshallCystic Fibrosis Foundation, Bethesda, Maryland, USA.
Lisa SaimanDepartment of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.
Gilead Sciences (United States) · USColumbia University Irving Medical Center · USCystic Fibrosis Foundation · USMaine Medical Center · USUniversity of Washington · US

Funding

Studies on bacterial populations and therapeutics for CF lung infectionsK24HL102246 · NHLBI · UNIVERSITY OF WASHINGTON · PI SINGH, PRADEEP K · 2010 to 2019
$1.6M
NHLBI NIH HHS K24 HL102246
6 · The paper itself

Abstract

The approval of aztreonam lysine for inhalation solution (AZLI) raised concerns that additional antibiotic exposure would potentially affect the susceptibility profiles of

Indexed as

Cystic FibrosisPseudomonas InfectionsAdministration, InhalationAnti-Bacterial AgentsAztreonamHumansLysineProspective StudiesPseudomonas aeruginosaTreatment OutcomeAnti-Bacterial AgentsAztreonamLysineantimicrobial drug resistanceaztreonamcystic fibrosisPseudomonas aeruginosa

Identifiers

PMID33318007
PMCPMC8092527
OpenAlexW3112181736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.